Citations 1
The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model
Chandrasekar, Aswath P. , Cummins, Nathan W. , Natesampillai, Sekar, Misra, Anisha , Alto, Alecia , Laird, Greg M., Laird, Greg , Cummins, Nathan W , Badley, Andrew D.
Journal of Virology | November 30, 2022 | Volume: 96 | Issue: 24 | Pages: No page available
This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infectionin vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and perforin/granzyme B and synergistically enhances autologous NK and CD8 cells’ killing of target cells.